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Introduction {#sec1}
============

Maturity-onset diabetes of the young 1 (MODY1) is an autosomal dominant monogenic diabetes condition typically manifesting before the age of 25 years. This condition is caused by inactivating mutations in the hepatocyte nuclear factor 4A (*HNF4A*) gene ([@bib57]) and is characterized by defects in glucose-stimulated insulin secretion (GSIS) from the pancreatic β cells ([@bib6]). Owing to the inaccessibility of human pancreatic tissue, rodent models have traditionally been used to study the molecular mechanisms underlying MODY1. Unfortunately, conditional knockout of *Hnf4a* in mouse pancreatic β cells did not result in a diabetic phenotype, although GSIS is impaired ([@bib4], [@bib16], [@bib35]). More importantly, *Hnf4a*^+/-^ mice exhibit normal glucose tolerance ([@bib48]), indicating that rodent models do not accurately recapitulate the MODY1 phenotype in humans. Human induced pluripotent stem cell (hiPSC)-based disease modeling strategies ([@bib53]) therefore provide opportunities to investigate the impact of MODY1/*HNF4A* mutation on the development of the foregut lineage in humans. In particular, the ventral foregut endoderm gives rise to progenitors that subsequently form the liver, whose development and function is heavily dependent on regulation by HNF4A, or the pancreatic β cells, which are known to be implicated in MODY1 pathophysiology.

HNF4A is a member of the steroid hormone receptor superfamily and functions as a transcription factor upon homodimerization ([@bib47]). Its expression is regulated by either the P1 (proximal) or P2 (distal) promoter. The usage of alternate promoters and presence of alternative splicing results in up to 12 known *HNF4A* isoforms that are expressed in a developmental stage- and tissue-specific manner ([@bib9], [@bib20], [@bib23], [@bib24], [@bib49]). Therefore *HNF4A* expression is dynamically regulated to ensure proper formation and function of multiple organs, in particular, the liver and pancreas ([@bib28]), which are the tissues we focus on in our study.

Knockout of *Hnf4a* in mice is dispensable for early development of the liver, whereas it is required for driving hepatic specification at later stages and in maintaining proper liver function ([@bib31]). In an early human pluripotent stem cell differentiation study, *HNF4A* was found to be necessary for establishing the hepatic gene regulatory network and induction of hepatic cell fate ([@bib8]). This correlates with the observation that patients with an inactivating *HNF4A* mutation exhibit alterations in liver function ([@bib14], [@bib41], [@bib44]). In addition to the liver, Hnf4a is also expressed in the maturing pancreas in mice and is largely confined to the developing islet and acinar cells ([@bib37]). A recent study showed that MODY1/*HNF4A* mutation does not prevent formation of INS^+^ cells from *in vitro* differentiations ([@bib55]). Nonetheless, the molecular and transcriptional impacts of heterozygous *HNF4A* mutation on early foregut endoderm, liver, and pancreas development leading to disease onset in humans remain largely unexplored.

We hypothesized that the MODY1/*HNF4A* mutation affects early human foregut development that can potentially lead to both liver and pancreas developmental defects. To circumvent the lack of access to human tissues during early development, we generated hiPSCs from members of a MODY1 family (with and without heterozygous *HNF4A* mutation) and differentiated them into hepatopancreatic foregut endoderm (henceforth termed *hepatopancreatic progenitors* \[HPPs\]), as well as hepatic and pancreatic β-like cells using independent, established protocols. Our data indicate that *HNF4A* haploinsufficiency, as a result of a loss-of-function MODY1 mutation, affects early human foregut development and that this deficiency is propagated to both hepatic and pancreatic cell fates. Our human disease model provides a platform for investigating why patients with MODY1 have specific hepatic and β cell developmental defects.

Results {#sec2}
=======

Establishing a MODY1 Disease Model Using Patient-Derived iPSCs {#sec2.1}
--------------------------------------------------------------

We previously reported the recruitment of two members of a MODY1 family harboring a heterozygous p.Ile271fs mutation in HNF4A ([Figure 1](#fig1){ref-type="fig"}A) ([@bib54]) resulting in premature truncation of the protein ([Figure 1](#fig1){ref-type="fig"}B). To facilitate rigorous and comprehensive hiPSC-based MODY1 disease modeling, we recruited more members of the same family and rederived a total of nine hiPSC lines composed of MODY1-hiPSCs from two patients (iN904-2 and iN904-1A/B/C) and control-hiPSCs from two non-diabetic family members (iN904-13A/B and iN904-7A/B/C) ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}). Using a previously published 17-day foregut endoderm differentiation protocol, we observed that *HNF4A* expression peaked at day 14 (D14) ([Figures 1](#fig1){ref-type="fig"}C and 1D) ([@bib52], [@bib51]), and that ∼70% of D14 HPPs were HNF4A^+^ ([Figure S2](#mmc1){ref-type="supplementary-material"}A), thereby providing a suitable model for studying *HNF4A* gene function and disease mechanisms underlying MODY1.Figure 1*HNF4A* Mutation (p.Ile271fs) Causes Impaired Foregut/Early Hepatopancreatic Progenitor (HPP) Development(A) MODY1 family node showing non-diabetic control-hiPSCs (iN904-13 and iN904-7) and MODY1-hiPSCs (iN904-2 and iN904-1).(B) p.Ile271fs mutation results in C-terminally truncated HNF4A that lacks part of the ligand-binding domain (LBD) and the entire F repressor domain (not drawn to scale).(C) The 17-day differentiation protocol for generating foregut endoderm and HPPs.(D) qPCR analysis of *HNF4A* expression during HPP differentiation.(E) qPCR analyses of *HNF4A* transcripts and foregut endoderm markers such as *HHEX*, *HNF1B*, *PDX1*, *GATA4, and RFX6* in control and MODY1-HPPs.(F) Immunofluorescent confocal images showing the localization of HNF4A protein in control and MODY1-HPPs, based on antibodies targeting the N- or C-terminal regions of HNF4A. Blue, DAPI; green, HNF4A; scale bars, 50 μm. White arrows point to the nuclear or cytoplasmic localization signal of HNF4A. Confocal images were acquired using similar scan settings across samples.Data are represented as mean ± SD of n = 3; representative of three independent experiments. \*p \< 0.05 versus D0 or control samples by Student\'s t test. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

HNF4A Mutation (p.Ile271fs) Causes Impaired Foregut/Early HPP Development {#sec2.2}
-------------------------------------------------------------------------

To elucidate the effects of the p.Ile271fs mutation, we simultaneously differentiated control- and MODY1-hiPSCs into HPPs. Both control- and MODY1-hiPSCs were able to differentiate into definitive endoderm cells at day 3 of differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}B). At D14 of differentiation, although we observed no obvious morphological differences between control- and MODY1-HPPs ([Figure S2](#mmc1){ref-type="supplementary-material"}C), the MODY1-HPPs expressed significantly lower levels of total *HNF4A* ([Figure 1](#fig1){ref-type="fig"}E). In fact, wild-type (WT) HNF4A protein was expressed at markedly lower levels in MODY1-HPPs based on protein expression data despite the presence of one copy of the WT allele at *HNF4A* ([Figure S2](#mmc1){ref-type="supplementary-material"}D). To determine if P1- or P2-driven *HNF4A* transcripts were affected, we carried out isoform-specific qPCR analyses and showed that both P1- and P2-driven forms of *HNF4A* are potentially affected in the D14 HPPs ([Figure S2](#mmc1){ref-type="supplementary-material"}E).

We further detected lower levels of foregut endoderm genes *HHEX*, *HNF1B*, *PDX1*, *GATA4,* and *RFX6* in the MODY1-HPPs, whereas no differences were observed for other pancreas-related genes *SOX9* or *MNX1* ([Figure 1](#fig1){ref-type="fig"}E), reflecting a downregulation of specific gene targets of *HNF4A* affected by the p.Ile271fs mutation rather than a global downregulation of pancreatic developmental genes. Downregulation of PDX1 and GATA4 was confirmed at protein level by immunofluorescence staining ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Subsequent immunofluorescence analyses additionally revealed that HNF4A protein is largely sequestered in the cytoplasm of the MODY1-HPPs as opposed to the predominant nuclear localization observed in control-HPPs ([Figure 1](#fig1){ref-type="fig"}F). Mislocalization of the HNF4A protein could further account for the loss of its function as a transcription factor.

RNA Sequencing Analyses Reveal Downregulation of Pancreas- and Liver-Related Genes and Upregulation of Caudal *HOX* Genes {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------

To thoroughly evaluate the genome-wide effects of the MODY1 mutation on foregut development, we performed RNA sequencing analyses on control and MODY1-hiPSC-derived D14 HPPs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed that genes involved in MODY and numerous liver functions were significantly downregulated ([Figure 2](#fig2){ref-type="fig"}A), consistent with the known functions of HNF4A target genes ([@bib5], [@bib39]). The affected genes were involved in processes related to steroid metabolism and lipoprotein and sterol binding and transport ([Figure S3](#mmc1){ref-type="supplementary-material"}A), providing clues to the role of HNF4A target genes. On the other hand, genes involved in DNA binding, transcription factor, and channel activity were upregulated, possibly due to compensatory regulatory mechanisms ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 2RNA Sequencing Analyses Reveal Global Transcriptional Changes Induced by the *HNF4A* Mutation in MODY1-HPPs at D14(A--C) (A) Analysis of downregulated genes via the KEGG pathway. Heatmap analyses of (B) pancreas-related and (C) liver-related genes that are downregulated with fold change (FC) \> 1.5, p \< 0.05.(D) Heatmap analyses of numerous caudal *HOX* genes involved in hindgut specification that are upregulated with FC \> 1.5, p \< 0.05. Colors in the heatmap depict gene expression in units of SD from the mean across all samples (upregulation in red, downregulation in blue). Controls indicated as 13A, 13B, 7A, 7B, and 7C; MODY1 indicated as 2, 1A--1C.(E) qPCR analyses of caudal *HOX* gene expression in control and MODY1-HPPs.Data are represented as mean ± SD of n = 3, representative of four independent experiments. \*p \< 0.05 versus control samples by Student\'s t test. See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Heatmap analyses revealed that a subset of pancreas-related genes was downregulated in MODY1-HPPs (fold change \[FC\] \> 1.5; p \< 0.05) ([Figure 2](#fig2){ref-type="fig"}B), including *PDX1*, the *FOXA* gene family, *GATA4*, *RFX6*, *HNF1B*, *KRT19,* and *SOX17*. In addition, numerous hepatic genes such as the apolipoprotein (*APO*) genes, *AFP*, *TTR,* and *HHEX* were also downregulated in the MODY1-HPPs ([Figure 2](#fig2){ref-type="fig"}C), consistent with findings from *Hnf4a*^*−/−*^ mice ([@bib31]). In contrast, we were intrigued to observe an upregulation of numerous caudal *HOX* genes including *HOXA10*, *HOXC11*, *HOXC12*, *HOXD11*, *HOXD12,* and *HOXD13* in the MODY1-HPPs ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S3](#mmc1){ref-type="supplementary-material"}C). Although some of the changes were modest, likely due to the fact that the HPP protocol is suited for foregut, but not hindgut, differentiation, the trend toward increased levels of hindgut markers suggests a potential switch away from foregut specification. Indeed, these caudal *HOX* genes are typically upregulated only in differentiation conditions favorable for hindgut formation (high fibroblast growth factor 2 concentration) ([@bib1]) in which hindgut marker *CDX2* is upregulated, but not foregut marker *HNF4A* ([Figure S3](#mmc1){ref-type="supplementary-material"}D). The loss of the repressor domain in HNF4A owing to the p.Ile271fs-truncating mutation may account for this "derepression" phenomenon.

MODY1-Mediated Loss of HNF4A Transcriptional Function Affects Subsequent Hepatic and Pancreatic Development Signatures {#sec2.4}
----------------------------------------------------------------------------------------------------------------------

Following the *HNF4A* loss-of-function observations in the HPPs, which are representative of a progenitor stage, we next investigated impacts on subsequent tissue development. We used established differentiation protocols that aimed to direct the differentiation of the hiPSCs into hepatocytes or pancreatic β-like cells ([@bib18], [@bib40]), as these are more representative of the liver and β cell differentiation process. First, time course differentiation of control-hiPSCs into hepatocyte-like cells ([@bib18]) revealed that *HNF4A* expression peaked on day 8 (D8), when 70%--80% HNF4A^+^ cells may be obtained, whereas other hepatic genes displayed peak expression on days 16 (D16) or 24 (D24) ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}A).Figure 3MODY1-Mediated *HNF4A* Haploinsufficiency in Early Foregut Development Affects Subsequent Hepatic and Pancreatic Development Signatures(A and B) (A) qPCR analyses showing pattern of hepatic gene expression over a 24-day differentiation in control-hiPSC-derived hepatic cells and (B) comparison of hepatic gene expression changes between control and MODY1 hepatic cells.(C and D) (C) qPCR analyses showing pattern of pancreatic β cell gene expression over a 35-day differentiation in control-hPSC-derived pancreatic β-like cells and (D) comparison of β cell gene expression changes between control and MODY1 pancreatic β-like cells.Data are represented as mean ± SD of n = 3, representative of three independent experiments. \*p \< 0.05 versus control samples by Student\'s t test. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

During hepatic differentiation, we noted that control-hiPSCs formed polygonal hepatocyte-like cells, whereas MODY1-hiPSCs did not ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In addition, MODY1 hepatic progenitors expressed significantly lower levels of *HNF4A* and *HHEX* on D8, leading to reduced expression of *HNF1A* and hepatoblast marker *AFP* on D16, and finally reduced levels of key mature hepatocyte markers *APOA2*, *APOB*, *APOC1*, *APOE,* and *ALB* on D24 as opposed to control cells ([Figure 3](#fig3){ref-type="fig"}B). Residual HNF4A protein expressed in the MODY1 hepatic progenitors appeared to localize largely to the cytoplasm when compared with the controls ([Figure S4](#mmc1){ref-type="supplementary-material"}), mirroring our earlier observations in the HPPs ([Figure 1](#fig1){ref-type="fig"}F). These data indicated that the early *HNF4A* loss-of-function effects (despite having a WT *HNF4A* allele) propagated into longer-term consequences that affected subsequent hepatic differentiation. This is consistent with the effects of shRNA-mediated knockdown of *HNF4A* in hPSCs that was reported previously ([@bib8]), although it is worth noting that a complete knockout of *HNF4A* in humans does not exist naturally.

We next investigated the impact of MODY1/*HNF4A* mutation on pancreatic β cell development using a published protocol for generating pancreatic β-like cells ([@bib40]). In differentiated WT β-like cells, *HNF4A* expression increased progressively over 35 days, together with other critical β cell transcripts such as *HNF1A*, *PDX1,* and *INS* ([Figure 3](#fig3){ref-type="fig"}C). Again, no difference was detected between the specification of control and MODY1 iPSCs into definitive endoderm cells, before the rise in HNF4A expression ([Figure S4](#mmc1){ref-type="supplementary-material"}D). However, in MODY1 β-like cells both *HNF4A* and *HNF1A* were significantly downregulated, although this was not the case for a number of other β cell genes tested at D35 ([Figure 3](#fig3){ref-type="fig"}D). Despite some reduction in *INS* transcript levels in MODY1-derived β-like cells ([Figure 3](#fig3){ref-type="fig"}D), we could detect the expression of C-peptide in both control- and MODY1-derived β-like cells ([Figure S4](#mmc1){ref-type="supplementary-material"}E). To corroborate the results observed in the MODY1-HPPs ([Figure 1](#fig1){ref-type="fig"}E), we also assessed gene expression changes in the pancreatic progenitors generated using the 35-day β cell differentiation protocol. We observed that the expression of *PDX1* and other progenitor markers was indeed reduced in the D13 pancreatic progenitors ([Figure S4](#mmc1){ref-type="supplementary-material"}F), although PDX1 reduction at protein level was not always consistently observed ([Figure S4](#mmc1){ref-type="supplementary-material"}G). We postulate that the early perturbations may be less apparent later in the differentiation owing to the exogenous stimuli that drive the differentiation of *PDX1*- and *INS*-expressing cells during β cell differentiation. Nonetheless, it was clear from our multiple differentiated cell models that loss in both *HNF4A* and *HNF1A* function in early hepatic and β cell development may contribute to the impaired tissue function in MODY1.

We then sought to define the molecular impact of HNF4A p.Ile271fs on its downstream targets including *HNF1A*, by evaluating the transcriptional potential of WT and mutant HNF4A in our hiPSC-derived hepatic differentiation models. As both P1- and P2-driven transcripts are present during foregut development ([Figure S2](#mmc1){ref-type="supplementary-material"}E), the effects of both WT and mutant HNF4A2 and HNF4A8 (longest isoforms representative of P1- and P2-driven expression, respectively) were evaluated. When expressed in the D8 hepatic progenitors, WT HNF4A2 significantly activated *HNF1A* promoter activity, whereas mutant HNF4A did not elicit the same effect ([Figure 4](#fig4){ref-type="fig"}A). Similarly, in the D16 hepatic progenitors, WT but not mutant HNF4A2 resulted in activation of the *APOB* promoter and *AFP* enhancer (containing a HNF4A-binding motif) ([@bib36]) ([Figures 4](#fig4){ref-type="fig"}B and 4C). The activation of the *AFP* enhancer by WT, but not mutant HNF4A2, was further replicated in HepG2 cells ([Figure 4](#fig4){ref-type="fig"}D), an AFP-producing human hepatoma cell line ([@bib25]). The lack of activation by mutant HNF4A may be explained in part by the reduced protein expression levels of mutant HNF4A compared with WT, although both HNF4A2/8 WT and mutants localized to the nuclei in the overexpression studies ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). In all experiments, WT HNF4A8 exhibited a weaker transactivation potential when compared with HNF4A2, and in the case of the *HNF1A* promoter and *AFP* enhancer, the effect was only significant in MODY1-derived cells where endogenous HNF4A function is reduced ([Figures 4](#fig4){ref-type="fig"}A and 4C).Figure 4MODY1/HNF4A Mutation Results in Loss of Ability to Activate Downstream Target Promoters in Hepatic and Pancreatic β Cells(A--D) Luciferase assays were performed to evaluate effects of WT or p.Ile271fs (Mut) HNF4A on the (A) *HNF1A* promoter, (B) *APOB* promoter, (C) *AFP* enhancer activity in hiPSC-derived hepatic cells, or (D) HepG2 cells. For (A--C), data are represented as mean ± SD n = 3, representative of two independent experiments. For (D), data are represented as mean ± SD of n = 12 from three independent experiments. \*p \< 0.05 versus GFP control in all hiPSC lines by two-way ANOVA; ^\#^p \< 0.05 versus GFP control in mutant hiPSC lines only by two-way ANOVA. \*\*p = 0.01 versus GFP control by Student\'s t test.(E) Chromatin immunoprecipitation qPCR analysis of HNF4A binding onto *HNF1A* promoter in EndoC-βH1 cells.(F) Small interfering RNA-mediated knockdown of *HNF4A* in EndoC-βH1 cells.(G) Luciferase assay evaluating *HNF1A* promoter activity upon knockdown of *HNF4A* and rescue. For (E--G), data are represented as mean ± SD of n = 12 from three to four independent experiments. \*p \< 0.05 versus IgG/GFP control as indicated by Student\'s t test.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

We further set out to investigate the regulation of *HNF1A* by HNF4A WT or mutants in human pancreatic β cells. As the suspension cell clumps generated from the pancreatic β cell differentiation were less amenable for *in vitro* assays unlike monolayer differentiation cultures, we used the human β cell line EndoC-βH1. Chromatin immunoprecipitation analyses in EndoC-βH1 showed that HNF4A was bound to the *HNF1A* promoter ([Figure 4](#fig4){ref-type="fig"}E), and subsequent knockdown of *HNF4A* by ∼55% resulted in a corresponding reduction in *HNF1A* promoter activation ([Figures 4](#fig4){ref-type="fig"}F and 4G). This effect could be rescued by WT HNF4A overexpression but not mutant HNF4A ([Figure 4](#fig4){ref-type="fig"}G). Overall, we have shown that HNF4A directly regulates the transcription of key components of developing hepatic and pancreatic β cells, and that the MODY1/HNF4A mutation (p.Ile271fs) results in the inability to activate target promoters. Our patient-derived iPSC-based model thus provides an *in vitro* platform for the interrogation of the underlying disease mechanisms in the hepatic and β cells.

MODY1 hiPSC-Derived Cells Express Both WT and Mutant *HNF4A* Transcripts and Do Not Exhibit Dominant Negativity {#sec2.5}
---------------------------------------------------------------------------------------------------------------

Finally, we sought to address the question of why the decrease in total *HNF4A* levels in MODY1-derived cells is beyond the expected 2-fold change given the presence of a WT allele in heterozygote carriers. We first determined the expression of WT and mutant *HNF4A* (p.Ile271fs) transcripts using a custom-designed allele-specific assay ([Figure S5](#mmc1){ref-type="supplementary-material"}C). As observed across multiple differentiated cell types, both WT and mutant *HNF4A* transcripts are expressed in the MODY1-derived cells, confirming heterozygosity at mRNA level ([Figures 5](#fig5){ref-type="fig"}A--5C). The detection of mutant transcripts indicated that there is an absence of complete nonsense-mediated decay (NMD) of the nonsense mutant transcripts ([@bib58]). Next, we checked if the MODY1 mutation could result in a dominant negative effect by co-expressing WT and mutant HNF4A to recapitulate a heterozygous condition. Gene regulatory assays showed that WT HNF4A was able to activate *AFP* enhancer activity normally in the presence of mutant protein, suggesting a lack of dominant negativity ([Figure 5](#fig5){ref-type="fig"}D). Given that HNF4A is also known to occupy its own promoter ([@bib5], [@bib39]), we performed further gene regulatory assays involving both the *HNF4A* P1 and P2 promoters and demonstrated that HNF4A can activate both promoters and subsequently its own expression in a feedforward manner ([Figure 5](#fig5){ref-type="fig"}E). Therefore loss of HNF4A function or mislocalization may result in failure to undergo autoregulation, accounting for overall reduced HNF4A expression in MODY1.Figure 5MODY1 hiPSC-Derived Cells Express Both WT and Mutant *HNF4A* Transcripts(A--C) Allele-specific qPCR analyses in (A) D14 HPPs, (B) D8 hepatoblasts, and (C) D35 β-like cells evaluating both WT and mutant *HNF4A* transcripts in MODY1-derived cells. Axes show relative fluorescence units for each allele-specific TaqMan probe, for a representative differentiation experiment.(D) Luciferase assays were performed to evaluate effects of WT and mutant HNF4A in combination with *AFP* enhancer activity in HepG2 cells.(E) Luciferase assays were performed to evaluate effects of HNF4A2 and HNF4A8 on *HNF4A* P1 and P2 promoter activities in Ad293 cells.Data are represented as mean ± SD of n = 4 independent experiments. \*\*p \< 0.01 versus GFP control unless otherwise indicated by Student\'s t test. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Earlier studies have reported *HNF4A* nonsense or missense gene mutations leading to either a loss-of-function or a dominant negative effect ([@bib27], [@bib29], [@bib46]). The p.Ile271fs mutation in our study introduces a frameshift and premature stop codon, which could lead to generation of unstable mRNA that may to some degree be degraded by NMD ([@bib13]), accounting for the overall lowered *HNF4A* levels in MODY1-hiPSC-derived cells. However, we did not observe complete NMD given that mutant transcripts were detectable in our MODY1-derived cells. At protein level, crystallographic studies have reported that several key residues of the ligand-binding domain are involved in charge-driven interactions that improve dimerization. Mutations in this region such as p.Ile271fs may therefore affect the formation of functional homodimers and impair DNA-binding activity, thereby abolishing transcriptional activity or coactivator recruitment ([@bib10], [@bib11], [@bib17], [@bib48]) to affect downstream gene regulation. Our work conclusively showed that loss of HNF4A-mediated gene regulation due to the p.Ile271fs mutation in a heterozygous state in MODY1 affected foregut endoderm gene expression signatures.

Our observations on caudal *HOX* gene upregulation led us to hypothesize that HNF4A typically functions to suppress ectopic hindgut *HOX* gene expression to facilitate proper foregut endoderm development, whereas this suppressive effect is disrupted in cells carrying the p.Ile271fs mutation. Further studies are required to determine whether *HOX* gene derepression is indirect, or if HNF4A requires other co-factors for its repressor function. Future work should also determine whether p.Ile271fs affects the specific interaction of HNF4A with ligands or co-factors important for its function. We propose that the impact of HNF4A haploinsufficiency on the specification of the foregut versus hindgut lineage is cell autonomous given the well-established function of HNF4A as a transcription factor. Nonetheless, the possibility of non--cell autonomy cannot be ruled out as previous studies have provided evidence for non-cell-autonomous functions of homeobox genes and other early developmental genes ([@bib2], [@bib3]). Future experiments that involve fluorescent labeling of the WT and mutant MODY1 hiPSCs followed by differentiation and fluorescence-activated cell sorting analyses may shed light on this.

HNF4A has been reported to be important for rodent hepatocyte development ([@bib31]) and is essential for specifying the early hepatic differentiation program ([@bib8]). However, the impact of MODY1/*HNF4A* mutation on hepatic development in humans has not been explored, given the intractability of human liver tissue. Here, we capitalize on our patient-derived iPSCs and ability to differentiate them into multiple relevant cell types to model cell-type-specific phenotypes and investigate underlying disease mechanisms. Our results indicated that the early loss of *HNF4A* expression in hepatoblasts propagated to long-term consequences on hepatic cell fate, as seen in the reduced expression of *ALB* and numerous *APO* genes. This is consistent with observations that patients with MODY1 with an inactivating HNF4A mutation exhibit reduced secretion of hepatocyte-specific proteins such as APOs ([@bib30], [@bib41], [@bib44]). Nonetheless, these alterations in liver function may not be clinically significant given the lack of reports on liver deformities or severe liver dysfunction in these patients. Given the potential redundancy within the complex liver transcription factor network that HNF4A is involved in ([@bib28], [@bib39]), there may be redundant mechanisms such as those involving HNF1A or ONECUT1 in the liver, or other compensatory mechanisms that enable largely normal liver development *in vivo* ([@bib38]).

We also confirmed that although both P1- and P2-driven *HNF4A* are expressed during foregut differentiation, the primary isoform(s) that activates expression of key target genes such as *HNF1A* and *AFP* is likely encoded by the P1 promoter. These results are consistent with previous reports ([@bib9]) that P1-driven isoforms exhibit greater transcriptional potential than their P2-driven counterparts, and we show that this is the case in both human hepatic cells and β cells.

Besides a liver phenotype, patients with MODY1 are known to exhibit progressive β cell insulin secretory defects ([@bib21], [@bib43]). Our studies provide valuable insights relating to the expression of early pancreatic genes affected by *HNF4A* haploinsufficiency such as *HNF1B*, *PDX1*, *GATA4,* and *RFX6* in the pancreatic progenitors. Although key developmental genes may be perturbed at the progenitor stage, the terminally *in vitro*-differentiated β-like cells were still able to express select β cell markers and C-peptide. This observation is in line with a previous study also involving MODY1-derived cells ([@bib55]). However, the study did not provide data from any of the progenitor stages. In both our study and that by Vethe et al., the *in vitro* differentiations do not generate β-like cells that are functionally mature despite the presence of insulin, therefore the functional capacity of these cells cannot be appropriately elucidated. As HNF4A haploinsufficiency involves a heterozygous mutation, there could be compensatory effects that result in a reset of the regulatory network, therefore patients do not have pancreatic agenesis. Nonetheless, there is a distinctive decrease in *HNF1A* expression in our MODY1-derived β-like cells. These findings are also consistent with the prevailing notion that MODY1/HNF4A is clinically and genetically linked to MODY3/HNF1A considering that HNF4A directly regulates the expression of *HNF1A* ([@bib12], [@bib29]). Detailed assessment of how the HNF4A-HNF1A cross-regulatory circuit and downstream transcriptional network is perturbed in both MODY1 and MODY3 may shed further light on the convergent and divergent role of both genes in governing tissue function, especially in human β cells.

It is notable that mutations in *HNF4A* are not only relevant to MODY1 but also have been associated with the more commonly occurring type 2 diabetes (T2D). Specifically, single nucleotide polymorphisms in both the P2 and P1 promoter regions and those near or within the *HNF4A* gene have been linked to T2D susceptibility ([@bib7], [@bib11], [@bib19], [@bib26], [@bib33], [@bib34], [@bib45], [@bib56]). Pancreatic islets isolated from donors with T2D were also found to exhibit reduced *HNF4A* expression ([@bib15]). Collectively, we report the successful establishment of a MODY1 hiPSC model with *HNF4A* haploinsufficiency that arose from a naturally occurring heterozygous mutation. Our findings highlight MODY1-*HNF4A* as a developmental disease that begins in the foregut endoderm and extends to its derivatives---in particular the liver and the pancreas. Our approach and results will have important implications for the study and understanding of diabetes pathogenesis in the context of MODY and even T2D.

Limitations of the Study {#sec3.1}
------------------------

In this study, we have validated our findings across multiple differentiation models that can generate known cell-type-specific markers, as well as established mechanisms in non-iPSC-based cell lines to substantiate our findings of HNF4A haploinsufficiency. However, there are well-recognized limitations of iPSC-based disease models that can affect the interpretation of results. First, the differentiation process is heterogeneous and therefore a bulk analysis approach may result in data with overall increased variability and reduced magnitude of effect. To circumvent this, single-cell studies may be used to interrogate cellular phenotypes at single-cell resolution ([@bib42]). Second, the use of isogenic controls generated using genome-editing tools may also help to reduce noise when compared with the use of family controls, which are still subject to differences in genetic background ([@bib50]). Next, directed differentiation protocols rely on the use of a cocktail of small molecules and growth factors to drive the differentiation process *in vitro*. This assumes that patient cells encounter these signals under an *in vivo* setting to drive tissue development. Therefore, an *in vitro* model may not accurately capture disease progression. On the contrary, currently available pancreatic β cell differentiation protocols are often unable to generate functional β cells *in vitro* and require transplantation into mice for *in vivo* maturation ([@bib22], [@bib32]). This hints at yet unknown molecular factors that are required to obtain β cells that can produce and secrete insulin in response to glucose stimuli. Therefore evaluation of the insulin secretory capacity of the MODY1-derived cells in the current differentiation model was not possible. Overcoming a number of these limitations will undoubtedly increase experimental robustness and reproducibility.
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All methods and can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S5, and Table S2Table S1 Expression Values (RPKM) of hiPSC-Derived HPPs at D14 from RNA Sequencing Data, Related to Figures 2 and S3The first two columns indicate the gene ID and official gene symbol for all protein-coding genes in the dataset. FPKM values are shown for control-hiPSC-derived cells (13A, 13B, 7A, 7B, and 7C) and MODY1-hiPSC-derived cells (2, 1A, 1B, and 1C).
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